INTENSITY THERAPEUTICS, INC. 8-K

What Happened
Intensity Therapeutics, Inc. announced in an 8-K (filed Feb 13, 2026) that it has filed a Certificate of Amendment with the Delaware Secretary of State to effect a 1-for-25 reverse stock split of its common stock. The reverse split becomes effective at 4:01 p.m. Eastern Time on February 18, 2026, and shares are expected to trade on The Nasdaq Capital Market on a post-split basis at the open on February 19, 2026 under the same ticker, INTS.

Key Details

• Reverse split ratio: 1-for-25 (every 25 pre-split shares → 1 post-split share).
• Effective time: 4:01 p.m. ET on February 18, 2026; expected trading on Nasdaq begins Feb 19, 2026.
• Fractional shares: holders entitled to cash in lieu of fractional shares, based on the closing sale price on Nasdaq on Feb 18, 2026, adjusted for the split.
• Equity adjustments: exercise prices and share amounts for outstanding stock options, warrants, convertible securities, and shares issuable under incentive plans will be proportionately adjusted.
• No change to the number of authorized shares; new CUSIP after split: 45828J202.
• The company issued a press release about the reverse split (filed as Exhibit 99.1).

Why It Matters
A reverse stock split reduces the number of outstanding shares and increases the per-share price proportionally, but does not change the company’s market capitalization by itself. Investors should expect their share counts to be reduced by a 25-to-1 ratio (with cash paid for any fractional shares) and see corresponding adjustments to any stock options or warrants they hold. The listing will remain on Nasdaq under the same ticker (INTS) with a new CUSIP, so trading continuity is maintained.